Patents Assigned to Valeant International (Barbados) SRL
-
Publication number: 20130004575Abstract: A controlled release pharmaceutical composition comprises (a) topiramate or a pharmaceutically acceptable salt thereof, (b) a first intelligent polymer component; and (c) a second intelligent polymer component having opposite wettability characteristics to the first intelligent polymer component. The polymer components are effective for controlled release of the pharmaceutically active substance from the composition.Type: ApplicationFiled: December 30, 2011Publication date: January 3, 2013Applicant: VALEANT INTERNATIONAL (BARBADOS) SRLInventors: Tien Nghiem, Graham Jackson
-
Publication number: 20120231081Abstract: The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55° C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups.Type: ApplicationFiled: May 18, 2012Publication date: September 13, 2012Applicant: VALEANT INTERNATIONAL (BARBADOS) SRLInventor: Steven FRISBEE
-
Publication number: 20120231080Abstract: The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55° C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups.Type: ApplicationFiled: May 18, 2012Publication date: September 13, 2012Applicant: VALEANT INTERNATIONAL(BARBADOS) SRLInventor: Steven FRISBEE
-
Publication number: 20120232156Abstract: The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55° C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups.Type: ApplicationFiled: May 18, 2012Publication date: September 13, 2012Applicant: VALEANT INTERNATIONAL(BARBADOS) SRLInventor: Steven E. FRISBEE
-
Publication number: 20120231046Abstract: The invention concerns an injection implant for filling up wrinkles, thin lines, skin cracks and scars, for reparative or plastic surgery, aesthetic dermatology, and for filling up gums in dental treatment. The invention concerns the use of biologically absorbable polymer microspheres or microparticles suspended in a gel. Said suspension is produced either ready-for-use or freeze-dried. The biological absorbability of the microspheres is controlled and enables the production of implants having well defined persistence and deliberately limited to 3 years.Type: ApplicationFiled: May 21, 2012Publication date: September 13, 2012Applicant: VALEANT INTERNATIONAL (BARBADOS) SRLInventors: Jérôme ASIUS, Hatem FESSI, Franck GOUCHET, Bénédicte LAGLENNE, Elisabeth LAUGHER-LAGLENNE
-
Publication number: 20120208773Abstract: The present invention provides for a pharmaceutical composition that includes tetrabenazine and a release-retarding agent; and a method of treating a hyperkinetic movement disorder (e.g., Huntington's disease, chorea associated with Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, myoclonus, dystonia and/or Tourette's syndrome). The method includes administering an effective amount of the pharmaceutical composition, for a period of time effective to treat the hyperkinetic movement disorder.Type: ApplicationFiled: August 12, 2010Publication date: August 16, 2012Applicant: Valeant International (Barbados) SRLInventors: Andrew John Duffield, Graham Jackson, Steven E. Frisbee, Okponanabofa Eradiri, John CK Lai
-
Patent number: 8158147Abstract: The present invention relates to a modified release composition of at least one form of tramadol which is a delayed and extended release composition for oral administration suitable for once daily dosing. That composition comprises a core comprising at least one form of tramadol selected from the group consisting of tramadol, racemic mixtures thereof, enantiomers thereof, pharmaceutically acceptable salts thereof, and combinations thereof in combination with a pharmaceutically acceptable excipient. That composition further comprises a modified release coating which substantially surrounds said core. The compositions of the invention provide delayed and extended release of said at least one form of tramadol such that the mean plasma concentration of the at least one form of tramadol reaches a therapeutically effective level at a time which is after at least about 3 hours after first administration.Type: GrantFiled: October 30, 2007Date of Patent: April 17, 2012Assignee: Valeant International (Barbados) SRLInventors: Pawan Seth, Paul J. Maes
-
Publication number: 20120082729Abstract: The invention provides a composition useful for making oral dosage forms capable of dissolving in the mouth in less than 40 seconds without the need for a conventional super disintegrant and having a friability of less than 1%; wherein the composition includes liquiflash particles and an excipient mass. A preferred excipient mass according to the invention contains a directly compressible inorganic salt; a cellulose derivative or a combination of a directly compressible inorganic salt and a cellulose derivative. Preferably, the liquiflash particles and the excipient mass are combined in proportions such that the active ingredient remains substantially within the microspheres when the composition is compressed to obtain a dosage form having a hardness of 20 to 50 N. The compositions of the invention allow for the fabrication of oral dosages having improved hardness and friability.Type: ApplicationFiled: December 8, 2011Publication date: April 5, 2012Applicant: VALEANT INTERNATIONAL (BARBADOS) SRLInventors: Naima MEZAACHE, Steven E. Frisbee, Patrick B. Woodall, Mark R. Herman
-
Patent number: 8128957Abstract: The present invention relates to a modified release composition of at least one form of tramadol which is a delayed and extended release composition for oral administration suitable for once daily dosing. That composition comprises a core comprising at least one form of tramadol selected from the group consisting of tramadol, racemic mixtures thereof, enantiomers thereof, pharmaceutically acceptable salts thereof, and combinations thereof in combination with a pharmaceutically acceptable excipient. That composition further comprises a modified release coating which substantially surrounds said core. The compositions of the invention provide delayed and extended release of said at least one form of tramadol such that the mean plasma concentration of the at least one form of tramadol reaches a therapeutically effective level at a time which is after at least about 3 hours after first administration.Type: GrantFiled: September 3, 2004Date of Patent: March 6, 2012Assignee: Valeant International (Barbados) SRLInventors: Pawan Seth, Paul J. Maes
-
Patent number: 8110219Abstract: The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55° C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups.Type: GrantFiled: December 5, 2008Date of Patent: February 7, 2012Assignee: Valeant International (Barbados) SRLInventor: Steven Frisbee